State Street SPDR S&P Biotech ETF
809 hedge funds and large institutions have $16.7B invested in State Street SPDR S&P Biotech ETF in 2026 Q1 according to their latest regulatory filings, with 106 funds opening new positions, 250 increasing their positions, 240 reducing their positions, and 93 closing their positions.
New
Increased
Maintained
Reduced
Closed
more ownership
Funds ownership: →
more funds holding in top 10
Funds holding in top 10: →
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
1% more capital invested
Capital invested by funds: $16.5B → $16.7B (+$192M)
0% less funds holding
Funds holding: 812 → 809 (-3)
54% less call options, than puts
Call options by funds: $2.19B | Put options by funds: $4.74B
Holders
809
Holding in Top 10
22
Calls
$2.19B
Puts
$4.74B
Top Buyers
| 1 | +$570M | |
| 2 | +$370M | |
| 3 | +$212M | |
| 4 |
Barclays
London,
United Kingdom
|
+$118M |
| 5 |
Morgan Stanley
New York
|
+$105M |
Top Sellers
| 1 | -$771M | |
| 2 | -$355M | |
| 3 | -$256M | |
| 4 |
Citigroup
New York
|
-$233M |
| 5 |
Two Sigma Investments
New York
|
-$177M |
